Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies
- 20 April 2008
- journal article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 333 (1-2) , 51-60
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapyJournal of Experimental Medicine, 2006
- Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cellsLeukemia & Lymphoma, 2005
- Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFNJournal of Experimental Medicine, 2004
- Antibodies and gene therapy: teaching old ‘magic bullets’ new tricksTrends in Immunology, 2004
- Magic bullets hit the targetNature, 2002
- Antibody-Targeted Immunotherapy for Treatment of MalignancyAnnual Review of Medicine, 2001
- The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1HMolecular Immunology, 1995
- IMPORTANCE OF ANTIGEN SPECIFICITY FOR COMPLEMENT‐MEDIATED LYSIS BY MONOCLONAL ANTIBODIESEuropean Journal of Immunology, 1988
- T CELL DEPLETION WITH CAMPATH-1 IN ALLOGENEIC BONE MARROW TRANSPLANTATIONTransplantation, 1988
- The Influence of Antigen Density and a Comparison of IgG and IgM Antibodies in the Anti‐Complementary Modulation of Lymphocytic Surface ImmunoglobulinScandinavian Journal of Immunology, 1982